Study of Clinical & Immune Severity Profiles of Patients Infected With

Status Recruiting

Clinical Trial Summary

The SARS-CoV2 virus causes severe or even fatal disease in a fraction of infected people. The clinical severity is based on a complicated pneumopathy with acute respiratory distress syndrome that can lead to multi-visceral failure. The underlying mechanism is a cytokinergic storm, an emerging facet of immunological dysregulation. This clinical trial is aimed to understand the mechanisms of this immunological dysregulation in order to identify therapeutic levers. The main objective is to understand the relationships between clinical severity, death or morbidity of resuscitation management, and immune status (i.e., immune pathways activated or not). Immune status will be investigated at many levels of organization (i.e., circulating leukocytes, cytokines and chemokines, transcripts). The secondary objectives are : - to understand what is responsible for clinical severity, viral load, or immune activation; - to highlight the consequences of immunological dysregulation on associated risks (i.e., immunosuppression leading to the emergence of infectious comorbidities) as well as the functioning of neurotransmission through metabolic pathway diversions. The impact of dysimmunity on these biological pathways will be assessed with a metabolomic analysis; - to understand the mechanisms of vulnerability related to the field. Moreover, while co-morbidities are likely to be a risk factor for severe disease progression, there are many situations in which they do not occur. Stress, with its neurovegetative and endocrinological dimensions, modulates the immune response. It is essential to know whether the stress response plays a role in immunological dysregulation. This analysis is a prerequisite for understanding the conditions of treatment with glucocorticoids. Angiotensin converting enzyme type 2 (ACE2) also plays a likely role in host viral infection. It is also thought to play an important role in the emergence of severe syndromes by affecting the quality of vascular response.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04365166
Study type	Observational
Source	Direction Centrale du Service de Santé des Armées
Contact	Nicolas LIBERT, MD, PhD
Phone	141466772
Email	nicolas.libert@intradef.gouv.fr
Status	Recruiting
Phase
Start date	April 21, 2020
Completion date	April 21, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05525494` - Patient Portal Flu Vaccine Reminders (5)	N/A
Completed	`NCT04537663` - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults	Phase 4
Terminated	`NCT04583280` - A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)	Phase 3
Completed	`NCT03321968` - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults	Phase 3
Active, not recruiting	`NCT03251196` - TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB
Completed	`NCT02561871` - A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers	Phase 1
Completed	`NCT01911143` - A Retrospective, Blinded Validation of a Host-response Based Diagnostics	N/A
Terminated	`NCT02032056` - Effect of Probiotics in Reducing Infections and Allergies in Young Children During the Complementary Feeding Period	N/A
Completed	`NCT01419262` - DO IT Trial: Vitamin D Outcomes and Interventions In Toddlers	Phase 3
Terminated	`NCT01432080` - Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant	Phase 2
Completed	`NCT00984945` - Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults	Phase 1
Completed	`NCT00127686` - Effect of Honey and Dextromethorphan on Nocturnal Cough and Sleep	Phase 1
Active, not recruiting	`NCT01107223` - Long Term Effect of General Practitioner Education on Antibiotic Prescribing	N/A
Completed	`NCT03739112` - Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly	Phase 3
Completed	`NCT04144491` - Effect of L. Rhamnosus Yoba on RTI and Other Health Outcomes Among Children (3-6 Years) in Uganda	N/A
Completed	`NCT05318235` - Virus Interactions in the Respiratory Tract; a Cohort Study With Children
Active, not recruiting	`NCT04170348` - Daily Vitamin D for Sickle-cell Respiratory Complications	Phase 2
Completed	`NCT04525040` - ProbioKid as Prevention Among Kids With Frequent URTI	N/A
Completed	`NCT05535777` - Patient Portal Flu Vaccine Reminders_RCT 5 (LADHS)	N/A
Not yet recruiting	`NCT05914324` - Outpatient Pediatric Pulse Oximeters in Africa	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study of Clinical and Immune Severity Profiles of Patients Infected With SARS-Cov2 (COVID-19) — REACOVIM

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms